Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(1-3)-β-D-glucan (BDG) is a naturally occurring polysaccharide found in the cell walls of most fungi, yeast, algae, and some plants. In clinical medicine, BDG is widely utilized as a major diagnostic biomarker for the presumptive detection of invasive fungal infections (IFIs), such as candidiasis, aspergillosis, and Pneumocystis jirovecii pneumonia, using assays like the Fungitell test. Additionally, BDG is investigated as a biomarker for gut barrier integrity and fungal translocation, where elevated systemic levels indicate increased intestinal permeability. It is also commonly consumed as a dietary supplement (often derived from baker's yeast or oats) for its immunomodulatory properties, which are mediated through the activation of immune cells via pattern recognition receptors such as Dectin-1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (1-3)-β-D-glucan.